flow trial semaglutide kidney outcomes nejm 2024 hazard ratio FLOWing with the SemagluTIDE — NephJC Kidney Outcomes With Glucagon-Like Peptide-1
Description
The American Diabetes Association recommends monitoring hemoglobin A1c every three months until glycemic targets are achieved, then at least twice yearly
Some patients respond better to one medication than the other depending on tolerance and metabolic response
No sign that this medication is doing anything at all
They pop up, scam people, and disappear, all in the span of a few months
